CRISPR Therapeutics AG (CRSP) is a publicly traded Healthcare sector company. As of May 20, 2026, CRSP trades at $48.67 with a market cap of $4.68B and a P/E ratio of -7.51. CRSP moved +2.03% today. Year to date, CRSP is -11.97%; over the trailing twelve months it is +23.69%. Its 52-week range spans $30.04 to $78.48. Analyst consensus is buy with an average price target of $75.00. Rallies surfaces CRSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded CRSP stock?
Recent politician trading activity in CRSP includes disclosures from James Inhofe. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
CRSP Key Metrics
Key financial metrics for CRSP
Metric
Value
Price
$48.67
Market Cap
$4.68B
P/E Ratio
-7.51
EPS
$-6.47
Dividend Yield
0.00%
52-Week High
$78.48
52-Week Low
$30.04
Volume
1.52M
Avg Volume
0
Revenue (TTM)
$3.51M
Net Income
$-581.60M
Gross Margin
0.00%
Congressional Trades in CRSP
James Inhofe sale (partial) CRSP on Jan 5, 2021 (amount: $15.00K) for Self.
Recent politician trading activity in CRSP includes disclosures from James Inhofe. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in CRSP?
Yes. Rallies tracks politician and congressional stock disclosures for CRSP, including reported purchases, sales, dates, owners, and trade amounts when available.
Is CRSP research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRSP. It does not provide personalized investment advice.
